JY
AVIR icon

Jeff Yass’s Atea Pharmaceuticals AVIR Stock Holding History

Jeff Yass’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,700
Closed -$106K – 12310
2025
Q3 		$106K Buy
+36,700
New +$125K ﹤0.01% 11531
2025
Q1 		– Sell
-19,700
Closed -$66K – 12445
2024
Q4 		$66K Sell
19,700
-77,600
-80% -$258K ﹤0.01% 11564
2024
Q3 		$326K Sell
97,300
-82,200
-46% -$298K ﹤0.01% 9424
2024
Q2 		$594K Sell
179,500
-5,000
-3% -$18.6K ﹤0.01% 7856
2024
Q1 		$745K Buy
184,500
+155,100
+528% +$607K ﹤0.01% 7568
2023
Q4 		$89.7K Buy
+29,400
New +$89K ﹤0.01% 11406
2023
Q3 		– Sell
-33,800
Closed -$126K – 11992
2023
Q2 		$126K Buy
+33,800
New +$127K ﹤0.01% 10745
2023
Q1 		– Sell
-24,500
Closed -$118K – 12535
2022
Q4 		$118K Sell
24,500
-17,200
-41% -$87K ﹤0.01% 10787
2022
Q3 		$237K Buy
41,700
+5,900
+16% +$45.2K ﹤0.01% 10410
2022
Q2 		$254K Sell
35,800
-32,900
-48% -$225K ﹤0.01% 10009
2022
Q1 		$496K Sell
68,700
-3,800
-5% -$25.8K ﹤0.01% 9004
2021
Q4 		$648K Sell
72,500
-17,900
-20% -$279K ﹤0.01% 8459
2021
Q3 		$3.17M Buy
90,400
+19,700
+28% +$546K ﹤0.01% 4838
2021
Q2 		$1.52M Buy
70,700
+63,300
+855% +$1.9M ﹤0.01% 6604
2021
Q1 		$457K Buy
+7,400
New +$500K ﹤0.01% 9694

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's AVIR Position: Q2 2026 in Review

Jeff Yass reduced its Atea Pharmaceuticals (AVIR) stake by 83% in Q2 2026, selling an estimated $339K and leaving 13,710 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12742.

Jeff Yass first reported a position in AVIR in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.75M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jeff Yass held 13,710 shares of Atea Pharmaceuticals worth $63.8K as of Q2 2026.
  • Jeff Yass sold 68,125 Atea Pharmaceuticals shares in Q2 2026, an estimated $339K.
  • Atea Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12742 holding.
  • Jeff Yass first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Jeff Yass's Atea Pharmaceuticals position peaked at $2.75M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.